Boston Scientific Corporation (NYSE:BSX) is included in our list of the best stocks to buy right now. Boston Scientific (BSX) Expands Urology Portfolio with Valencia Deal, Analysts Emphasize Organic Growth A dose bottle of the medication is in the medical tech's hand On January 12, 2026, Boston Scientific Corporation (NYSE:BSX) shared an expansion update, announcing a definitive agreement to acquire Valencia Technologies. With this move, the company expands its Urology franchise into implantable tibial ...

Boston Scientific Corporation (NYSE:BSX) is one of the best blue-chip stocks to buy for 2026. Boston Scientific Corporation (NYSE:BSX) said on January 12 that it has agreed to acquire Valencia Technologies, maker of the FDA-approved eCoin System for urge urinary incontinence. The coin-sized implant, placed near the ankle, uses tibial nerve stimulation to help control bladder activity and showed a 68% response rate in clinical trials. The acquisition expands Boston Scientific’s urology and pelvic health por ...

Market Overview - Global markets are facing a mix of geopolitical risks, political uncertainty, and structural tailwinds, making stock selection critical for investors in 2026 [2] - U.S., European, and Japanese equities are expected to rise in 2026, but gains will be smaller compared to the previous year, with over half of market participants anticipating a correction [3] - Investor sentiment has been affected by recent "black swan" events, creating a "wall of worry" that markets have historically climbed [4] Methodology for Stock Selection - The list of best stocks was curated from the top 40 hedge fund holdings tracked by Insider Monkey, assessing analyst sentiment and upside potential [7] - The strategy has historically outperformed the market, returning 427.7% since May 2014, significantly beating its benchmark [8] Company Highlights Meta Platforms, Inc. (NASDAQ:META) - Hedge Fund Holders: 273, Upside Potential: 26.30% [10] - Wells Fargo lowered its price target from $802 to $795 but remains optimistic about Q4 earnings and 2026 outlook, projecting EPS of $31-$32 [11] - The company is expected to benefit from the release of the next-generation Llama model and associated AI-driven products [12] - Meta has secured long-term power purchase agreements for electricity from U.S. nuclear plants, reflecting rising demand for AI and data centers [13] - Focuses on social media and immersive technologies through its Family of Apps and Reality Labs segments [14] Boston Scientific Corporation (NYSE:BSX) - Hedge Fund Holders: 102, Upside Potential: 28.00% [15] - Announced acquisition of Valencia Technologies to expand its Urology franchise into implantable tibial nerve stimulation [16] - The eCoin System addresses a large market of overactive bladder, with only 19% of affected adults receiving treatment [16] - Goldman Sachs lowered its price target from $124 to $112 while maintaining a 'Buy' rating, focusing on organic growth in 2026 [18] MercadoLibre, Inc. (NASDAQ:MELI) - Hedge Fund Holders: 109, Upside Potential: 28.50% [19] - Over 90% of analysts are bullish, with a consensus price target of $2,800 [19] - Cantor Fitzgerald highlighted the potential for revenue growth driven by AI efficiencies, despite the sector trading 20% below medium-term valuations [20] - Wedbush reduced its price target from $2,800 to $2,700 while maintaining an 'Outperform' rating, citing increased spending and competition concerns [21] - Known for its leading e-commerce and fintech ecosystem in Latin America [22] Uber Technologies, Inc. (NYSE:UBER) - Hedge Fund Holders: 143, Upside Potential: 28.70% [23] - Facing a lawsuit that could significantly impact financial exposure and regulatory standing [24] - Management asserts that safety measures are in place, including background checks and partnerships with advocacy groups [25] - Operates a global technology platform connecting consumers with mobility, delivery, and freight services [26] Snowflake Inc. (NYSE:SNOW) - Hedge Fund Holders: 102, Upside Potential: 29.40% [27] - Announced acquisition of Observe to enhance its AI Data Cloud capabilities [28] - The platform aims to address the $51.7 billion IT operations management market, focusing on efficient anomaly detection [29] - Analyst sentiment is mixed, with Barclays downgrading the stock while Goldman Sachs initiated coverage with a 'Buy' rating [30] - Focuses on cloud-native data warehousing and enabling secure, scalable AI and analytics [31]

Key Takeaways Boston Scientific agreed to acquire Valencia Technologies, targeting a first-half 2026 close. BSX gains the eCoin implant for UUI, expanding into the implantable tibial nerve stimulation area.BSX's new deal should be immaterial to adjusted EPS in 2026 but more dilutive on a GAAP basis.Boston Scientific, Inc. (BSX) recently announced that it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held firm that develops solutions for treating bladder dy ...

Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions in the global medical technology sector this year. The acquisition is aimed at strengthening Boston Scientific's cardiovascular and vascular intervention portfolio, as the company looks to capitalise on rising demand for minimally invasive treatments for blood clots, stroke and other life-threatening conditions. ...

Core Viewpoint - Boston Scientific Corporation is a prominent player in the medical device industry, focusing on innovative solutions across various healthcare segments, particularly in interventional specialties like cardiology, urology, and neurology [1] Group 1: Company Developments - On January 14, 2026, Citigroup upgraded Boston Scientific's rating to "Buy," with the stock priced at $94.14, reflecting confidence in the company's strategic moves to enhance its market position [2] - The company announced a definitive agreement to acquire Valencia Technologies Corporation, which specializes in innovative solutions for bladder dysfunction, aiming to strengthen its urology offerings [4] Group 2: Financial Performance - Boston Scientific is experiencing an expansion in profit margins, driven by growth in its electrophysiology and WATCHMAN franchises, which is improving earnings quality and supporting growth in the MedTech sector [3] - The stock price of Boston Scientific is currently $94.14, with a market capitalization of approximately $139.6 billion, and a trading volume of 9,689,369 shares [5]